direct factor Xa inhibitors

     

Select
Display
Trial Studied trt Control trt patientstagsNCTROB Result

acute coronary syndrome

apixaban
APPRAISE-1 (10mg od), 2009apixabanplaceboNCT00313300Exploratory negative
APPRAISE-1 (2.5 mg bid), 2009apixabanplaceboNCT00313300 negative
APPRAISE 2, 2011apixabanplaceboNCT00831441Low risk of bias negative
APPRAISE japan ongoing apixabanplaceboNCT00852397Exploratory ongoing
dabigatran
REDEEM, 2009dabigatranplaceboNCT00621855negative
otamixaban
SEPIA-ACS1 TIMI 42, 2009otamixabanunfractionated heparinNCT00317395Exploratory suggesting
rivaroxaban
ATLAS ACS 2 - TIMI 51 (2.5mg), 2011rivaroxaban 2.5mgplaceboNCT00809965Low risk of bias suggesting
ATLAS ACS-TIMI 46 (2.5mg), 2009rivaroxaban 2.5mgplaceboNCT00402597negative
ATLAS ACS 2 - TIMI 51 (5mg), 2011rivaroxaban 5mgplaceboNCT00809965suggesting
ATLAS ACS-TIMI 46 (5mg), 2009rivaroxaban 5mgplaceboNCT00402597negative
ximelagatran
ESTEEM, 2003ximelagatranplaceboExploratory -

atrial fibrillation

apixaban
AVERROES, 2011apixabanaspirinineligible for VKANCT00496769Low risk of bias suggesting
ARISTOTLE, 2011apixabanwarfarin standard doseNCT00412984Low risk of bias conclusive
phase 2 apixabanapixabanwarfarin standard doseNCT00787150Exploratory -
edoxaban
Weitz (edoxaban phase 2)edoxabanwarfarin standard doseNCT00504556Exploratory -
phase 2 edoxabanedoxabanwarfarin standard doseNCT00806624Exploratory -
ENGAGE-AF TIMI 48 High dose, 2013edoxaban high dosewarfarin standard doseNCT00781391Low risk of bias suggesting
rivaroxaban
ROCKET-AF, 2010rivaroxabanwarfarin standard doseNCT00403767Low risk of bias suggesting
ROCKET J ongoing rivaroxabanwarfarin standard doseNCT00494871 ongoing

cardiovascular prevention

rivaroxaban
COMPASS (rivaroxaban alone), 2017rivaroxabanaspirinsecondary preventionNCT01776424 -
COMPASS (rivaroxaban + aspirin), 2017rivaroxaban + aspirinaspirinsecondary preventionNCT01776424Low risk of bias -

DVT prophylaxis

apixaban
ADVANCE 3, 2010apixabanenoxaparinNCT00423319Low risk of bias suggesting
ADVANCE 2, 2010apixabanenoxaparin (europe regimen)NCT00452530Low risk of bias suggesting
APROPOS 2.5mg, 2007apixabanenoxaparin (US regimen)NCT00097357Exploratory negative
ADVANCE-1, 2008apixabanenoxaparin (US regimen)NCT00371683Low risk of bias suggesting
edoxaban
DU176b-04 ongoing edoxabanplaceboNCT01203072 ongoing
DU176b-B-J302 ongoing edoxabanenoxaparinNCT01181102 ongoing
DU176b-B-J303 ongoing edoxabanenoxaparinNCT01181141 ongoing
DU176b-B-J304 ongoing edoxabanenoxaparinNCT01181167 ongoing
STARS J-Vedoxabanenoxaparin (short duration)NCT01181167Low risk of bias suggesting
rivaroxaban
RECORD 1, 2008rivaroxabanenoxaparinNCT00329628Low risk of bias suggesting
RECORD 3, 2008rivaroxabanenoxaparin (europe regimen)NCT00361894Low risk of bias suggesting
ODIXa-HIP 10mg, 2006rivaroxabanenoxaparin (short duration)Exploratory suggesting
RECORD 2, 2008rivaroxaban (long duration)enoxaparin (short duration)NCT00332020Low risk of bias suggesting
ODIXa-KNEE, 2005rivaroxabanenoxaparin (US regimen)Exploratory negative
RECORD 4, 2009rivaroxabanenoxaparin (US regimen)NCT00362232Low risk of bias suggesting

venous thrombosis

ximelagatran
THRIVE III, 2003ximelagatrandiscontinuationLow risk of bias suggesting